JP2004508366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508366A5 JP2004508366A5 JP2002525134A JP2002525134A JP2004508366A5 JP 2004508366 A5 JP2004508366 A5 JP 2004508366A5 JP 2002525134 A JP2002525134 A JP 2002525134A JP 2002525134 A JP2002525134 A JP 2002525134A JP 2004508366 A5 JP2004508366 A5 JP 2004508366A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- solvate
- salt
- functional derivative
- physiologically functional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- KMHXVUCYJPXSIV-DHDCSXOGSA-N (3z)-3-[[4-(1,2,4-triazol-1-yl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C\NC(C=C1)=CC=C1N1C=NC=N1 KMHXVUCYJPXSIV-DHDCSXOGSA-N 0.000 claims 1
- XAHMAJJMFALGCW-ZROIWOOFSA-N (3z)-3-[[4-(1h-1,2,4-triazol-5-yl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C\NC(C=C1)=CC=C1C=1N=CNN=1 XAHMAJJMFALGCW-ZROIWOOFSA-N 0.000 claims 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- HSHFQBBHYFYCQC-LGMDPLHJSA-N 3-ethyl-3-[4-[[(z)-(2-oxo-1h-indol-3-ylidene)methyl]amino]phenyl]piperidine-2,6-dione Chemical compound C=1C=C(N\C=C/2C3=CC=CC=C3NC\2=O)C=CC=1C1(CC)CCC(=O)NC1=O HSHFQBBHYFYCQC-LGMDPLHJSA-N 0.000 claims 1
- WPAUHINVDSQAEQ-FLIBITNWSA-N 5-[[(z)-(2-oxo-1h-indol-3-ylidene)methyl]amino]-1,3-dihydrobenzimidazol-2-one Chemical compound C1=C2NC(=O)NC2=CC(N/C=C2/C3=CC=CC=C3NC2=O)=C1 WPAUHINVDSQAEQ-FLIBITNWSA-N 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- JUULZRNMGDKYCG-YFHOEESVSA-N O1C(N)=NN=C1C1=CC=CC(N\C=C/2C3=C4N=NNC4=CC=C3NC\2=O)=C1 Chemical compound O1C(N)=NN=C1C1=CC=CC(N\C=C/2C3=C4N=NNC4=CC=C3NC\2=O)=C1 JUULZRNMGDKYCG-YFHOEESVSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
Claims (6)
- 式II：
Ｒ１は水素であり、
Ｒ２は水素であるか、
または場合によりＲ１及びＲ２は結合してトリアジン環である縮合環Hetを形成し、
Ｒ３は水素であり、
Ｒ４は
で示される化合物、またはその塩、溶媒和物、もしくは生理学的機能性誘導体。 - 5-｛[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ｝-1,3-ジヒドロ-2H-ベンズイミダゾール-2-オン、
(3Z)-3-｛[4-(1H-1,2,4-トリアゾール-1-イル)アニリノ]-メチレン｝-1,3-ジヒドロ-2H-インドール-2-オン、
3-エチル-3-(4-｛[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ｝フェニル)-2,6-ピペリジンジオン、
(8Z)-8-｛[3-(5-アミノ-1,3,4-オキサジアゾール-2-イル)アニリノ]メチレン｝-6,8-ジヒドロ[1,2,3]トリアゾロ[4,5-e]インドール-7(3H)-オン、
2-(4-｛[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ｝フェニル)アセトアミド、及び
(3Z)-3-｛[4-(1H-1,2,4-トリアゾール-3-イル)アニリノ]メチレン｝-1,3-ジヒドロ-2H-インドール-2-オン、
からなる群から選択される化合物、またはその塩、溶媒和物、もしくは生理学的機能性誘導体。 - 治療的有効量の請求項１もしくは２に記載の化合物、またはその塩、溶媒和物、もしくは生理学的機能性誘導体と、１種以上の製薬上許容し得る担体、希釈剤及び賦形剤を含有する医薬組成物。
- 治療に使用するための請求項１もしくは２に記載の化合物、またはその塩、溶媒和物、もしくは生理学的機能性誘導体。
- 不適切なTrkA活性によって仲介される障害の治療に使用するための医薬の製造における、請求項１もしくは２に記載の化合物、またはその塩、溶媒和物、もしくは生理学的機能性誘導体の使用。
- 不適切な分裂促進因子活性化型キナーゼ活性によって仲介される障害の治療に使用するための医薬の製造における、請求項１もしくは２に記載の化合物、またはその塩、溶媒和物、もしくは生理学的機能性誘導体の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22996600P | 2000-09-01 | 2000-09-01 | |
| PCT/US2001/026286 WO2002020513A1 (en) | 2000-09-01 | 2001-08-23 | Oxindole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508366A JP2004508366A (ja) | 2004-03-18 |
| JP2004508366A5 true JP2004508366A5 (ja) | 2005-05-19 |
Family
ID=22863416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002525134A Pending JP2004508366A (ja) | 2000-09-01 | 2001-08-23 | オキシインドール誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6964977B2 (ja) |
| EP (1) | EP1317446A1 (ja) |
| JP (1) | JP2004508366A (ja) |
| AU (1) | AU8664701A (ja) |
| WO (1) | WO2002020513A1 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| EP1556083B1 (en) | 2002-10-08 | 2011-02-02 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| EP2270048B1 (en) | 2002-12-24 | 2015-11-11 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| SG117798A1 (en) | 2003-06-23 | 2008-02-29 | Shell Int Research | Process to prepare a lubricating base oil |
| AU2005243247B2 (en) | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| MX2007004765A (es) * | 2004-10-25 | 2007-07-09 | Ligand Pharm Inc | Compuestos y metodos que modulan la actividad de la trombopoyetina. |
| PL2383268T3 (pl) | 2005-02-04 | 2016-02-29 | Astrazeneca Ab | Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy |
| PT1853588E (pt) | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
| JP2008540622A (ja) | 2005-05-16 | 2008-11-20 | アストラゼネカ アクチボラグ | 化合物 |
| WO2007049041A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
| WO2007123269A1 (ja) | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | アゾールカルボキサミド誘導体 |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
| RU2461551C2 (ru) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| US8426673B2 (en) | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
| WO2009135000A2 (en) * | 2008-04-30 | 2009-11-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| US9718775B2 (en) * | 2014-03-14 | 2017-08-01 | Milliken & Company | Oxindole compounds and compositions comprising the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6624171B1 (en) * | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| US6492398B1 (en) * | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
| US6498176B1 (en) * | 1999-03-04 | 2002-12-24 | Smithklinebeecham Corporation | 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| US6620818B1 (en) * | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
| ES2275021T3 (es) | 2001-09-27 | 2007-06-01 | Smithkline Beecham Corporation | Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico. |
-
2001
- 2001-08-23 US US10/362,739 patent/US6964977B2/en not_active Expired - Fee Related
- 2001-08-23 JP JP2002525134A patent/JP2004508366A/ja active Pending
- 2001-08-23 WO PCT/US2001/026286 patent/WO2002020513A1/en not_active Ceased
- 2001-08-23 AU AU8664701A patent/AU8664701A/xx active Pending
- 2001-08-23 EP EP01966107A patent/EP1317446A1/en not_active Withdrawn
-
2005
- 2005-08-03 US US11/196,597 patent/US20050282810A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7216682B2 (ja) | Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物 | |
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| ES2206292T3 (es) | Derivados de oxazol y tiazol como agentes activadores de la produccion/secrecion de neurotrofina. | |
| JP2020530446A5 (ja) | ||
| JP4974438B2 (ja) | ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体 | |
| EP2675801B1 (en) | Novel pyrazole and imidazole derivatives useful as orexin antagonists | |
| JP5647268B2 (ja) | 新規抗真菌性トリアゾール誘導体 | |
| JP2019077725A5 (ja) | ||
| US20080166359A1 (en) | Methods of using MEK inhibitors | |
| CA2799640C (en) | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) | |
| AU2009266756B2 (en) | Triazole derivative or salt thereof | |
| RU2008141761A (ru) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ | |
| US20090137596A1 (en) | G-protein inhibitor | |
| JP4974437B2 (ja) | ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体 | |
| JP2005525324A5 (ja) | ||
| RU2003107016A (ru) | Замещенные пиразолы | |
| JP2008520741A5 (ja) | ||
| JP2002517445A (ja) | ｃＧＭＰホスホジエステラーゼのキナゾリノン抑制剤 | |
| JP2013501749A5 (ja) | ||
| JP2004517848A (ja) | 抗ウイルス剤 | |
| JP2009528389A5 (ja) | ||
| JP2008507539A5 (ja) | ||
| JP2009538321A5 (ja) | ||
| RU2006127575A (ru) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| CA2442428A1 (en) | Novel tyrosine kinase inhibitors |